Treatment of saphenous vein graft lesions with drug-eluting stents Immediate and midterm outcome by Ge, Lei et al.
T
G
I
L
G
F
M
P
(
o
w
r
m
s
c
r
d
e
p
(
s
a
i
u
t
i
a
S
2
Journal of the American College of Cardiology Vol. 45, No. 7, 2005
© 2005 by the American College of Cardiology Foundation ISSN 0735-1097/05/$30.00
PInterventional Cardiology
reatment of Saphenous Vein
raft Lesions With Drug-Eluting Stents
mmediate and Midterm Outcome
ei Ge, MD,*† Ioannis Iakovou, MD,* Giuseppe M. Sangiorgi, MD,* Alaide Chieffo, MD,*
loria Melzi, MD,* John Cosgrave, MD,* Matteo Montorfano, MD,* Iassen Michev, MD,*
lavio Airoldi, MD,* Mauro Carlino, MD,* Nicola Corvaja, MD,* Antonio Colombo, MD, FACC*
ilan, Italy; and Shanghai, China
OBJECTIVES The purpose of the present report was to evaluate clinical and angiographic outcomes of
drug-eluting stent (DES) implantation in saphenous vein graft (SVG) lesions.
BACKGROUND The safety and efficacy of DES implantation for the treatment SVG lesions remains
uncertain.
METHODS We evaluated in-hospital and six-month outcomes in 61 consecutive patients treated with
DES in SVG lesions from March 2002 to March 2004 (DES group), as compared to 89
consecutive patients treated with bare-metal stents (BMS) in the 24 months immediately
before the introduction of DES (BMS group). Major adverse cardiac events (MACE)
including death, myocardial infarction, target lesion revascularization (TLR), and target
vessel revascularization (TVR) were recorded in-hospital and at six-month follow-up.
RESULTS The rate of in-hospital MACE was similar between the two groups (6.6% vs. 5.6%, p 1.0).
Cumulative MACE at six months was 11.5% in the DES group and 28.1% in the BMS group
(p  0.02). The DES group had a significantly lower incidence of in-segment restenosis
(10.0% vs. 26.7%, p  0.03), TLR (3.3% vs. 19.8%, p  0.003), and TVR (4.9% vs. 23.1%,
p  0.003). By Cox regression analysis, diabetes (hazard ratio [HR]: 3.03; 95% confidence
interval [CI]: 1.33 to 6.90; p  0.008), usage of BMS (HR: 2.53; 95% CI: 1.07 to 5.97;
p  0.03), and age of SVG (HR: 1.10; 95% CI: 1.02 to 1.19; p  0.02) were identified as
predictors of MACE at six-month follow-up.
CONCLUSIONS Compared to BMS implantation, DES implantation in SVG lesions appears safe with
favorable and improved mid-term outcomes. (J Am Coll Cardiol 2005;45:989–94) © 2005
ublished by Elsevier Inc. doi:10.1016/j.jacc.2004.11.060by the American College of Cardiology Foundation
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bercutaneous revascularization of saphenous vein graft
SVG) lesions remains a challenge for interventional cardi-
logists. Balloon angioplasty in SVG lesions is associated
ith a high complication rate and a high incidence of
estenosis (1,2). Compared to balloon angioplasty, bare-
etal stent (BMS) implantation in SVG lesions has been
hown to improve procedural outcomes and reduce major
ardiac events (3,4). However, the incidence of in-stent
estenosis remains 20% to 37% (3–5). Recently, the intro-
uction of drug-eluting stents (DES), either sirolimus-
luting stents (Cypher, Cordis, Johnson & Johnson Com-
any, Warren, New Jersey) or paclitaxel-eluting stents
Taxus, Boston Scientific, Natick, Massachusetts), has
hown promising results in selected de novo native coronary
rtery lesions (6–10). The safety and efficacy of DES
mplantation for the treatment of SVG lesions remains
ncertain (11). The aim of the present report was, therefore,
o evaluate clinical and angiographic outcomes of DES
mplantation in SVG lesions.
From the *EMO Centro Cuore Columbus and San Raffaele Hospital, Milan, Italy;
nd the †Department of Cardiology, Zhongshan Hospital, Fudan University,
hanghai, China.n
Manuscript received September 14, 2004; revised manuscript received October 29,
004, accepted November 2, 2004.ETHODS
e identified 61 consecutive patients (with 69 lesions) who
nderwent percutaneous revascularization in SVG lesions
sing DES from March 2002 to March 2004 (DES group).
uring this time period, an additional 103 patients were
reated for lesions located in SVGs; 25 of them were
ncluded in a registry utilizing a covered stent, and others
ere treated with BMS. The main reasons for utilizing
MS were: 1) a lesion 10 mm in length evaluated to be at
ow risk of restenosis; 2) a lesion located on an SVG with a
eference vessel diameter (RVD) 3.5 mm for which there
ere no appropriately sized DES available. A control group
BMS group) was composed of 89 consecutive patients
with 120 lesions) who underwent percutaneous treatment
n SVG lesions with BMS in the 24 months immediately
efore the introduction of DES. Patients were excluded if
ny of the following was present: an acute myocardial
nfarction (MI) 1 week before the index procedure,
mplantation of a covered stent, or brachytherapy.
All patients were pretreated with aspirin and either ticlopi-
ine or clopidogrel. A 300-mg loading dose of clopidogrel
efore the index procedure was administered if patients were
ot pretreated. During the procedure, patients received intra-
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Safety and Efficacy of DES in SVG Lesions April 5. 2005:989–94enous unfractionated heparin (100 IU/kg) to maintain acti-
ated clotting time between 250 to 300 s. Platelet glycoprotein
Ib/IIIa receptor inhibitors and distal protection devices were
sed at the discretion of the operator. Stent implantation
ethods have been described previously (12). All stents were
mplanted with high deployment pressure (12 atm). Patients
eceived lifelong aspirin and clopidogrel or ticlopidine for at
east three to six months after DES implantation and for at
east one month after BMS implantation.
linical definitions and follow-up. Clinical follow-up
as performed by either telephone contact or office visit at
months after the index procedure (follow-up window to
10 days). Angiographic follow-up was scheduled for be-
ween six and eight months after the procedure unless
linically indicated at an earlier time. The events analyzed in
his report included death (cardiac and noncardiac), MI
Q-wave and non–Q-wave), restenosis, stent thrombosis,
arget lesion revascularization (TLR), and target vessel
evascularization (TVR), either percutaneous or surgical.
All deaths were considered cardiac unless otherwise docu-
ented. A non–Q-wave MI was defined as creatine
inase-MB enzyme elevation 3  the upper limit of the
ormal value; when in addition to enzyme elevation there were
ew pathological Q waves on the electrocardiogram, the event
as defined as a Q-wave MI. Target lesion revascularization
as defined as repeat revascularization secondary to a stenosis
50% within the stent or within the 5-mm borders proximal
r distal to the stent at the follow-up angiogram. Target vessel
evascularization was defined as repeat revascularization within
he treated vessel. Stent thrombosis was defined as any of the
ollowing: angiographic documentation of intrastent filling
efect or stent occlusion associated with a clinical event,
nexplained sudden death, or MI after stent implantation and
ithout concomitant demonstration of a patent stent (13,14).
ajor adverse cardiac events (MACE) were defined as cardiac
eath, MI, TLR, and TVR. Cumulative MACE were defined
s the in-hospital and six-month follow-up MACE.
uantitative coronary angiographic analysis. Coronary
ngiograms were analyzed using a validated edge detection
ystem (CMS, version 5.2, MEDIS, the Netherlands).
inimal lumen diameter (MLD), RVD, and percent
iameter stenosis at baseline, post-procedure, and at
Abbreviations and Acronyms
BMS  bare-metal stent
CI  confidence interval
DES  drug-eluting stent
HR  hazard ratio
MACE  major adverse cardiac events
MI  myocardial infarction
MLD  minimal lumen diameter
RVD  reference vessel diameter
SVG  saphenous vein graft
TLR  target lesion revascularization
TVR  target vessel revascularizationollow-up were measured, respectively. Acute gain was (efined as the difference between the MLD immediately
fter the procedure and the baseline. Late lumen loss was
efined as the difference between the MLD immediately
fter the procedure and at follow-up (15). Angiographic
estenosis was defined as diameter stenosis 50% by quan-
itative coronary angiographic analysis within a previously
tented segment (stent and 5 mm proximal and distal) at the
ollow-up angiogram. No reflow was defined as Thrombol-
sis In Myocardial Infarction (TIMI) (16) flow grade 1
hat was not due to dissection or high-grade residual
tenosis adjacent to the target lesion (17). Angiographic
uccess was defined as a final residual stenosis 30% with
IMI flow grade 3. Procedural success was defined as the
chievement of angiographic success without in-hospital
ACE.
tatistical analysis. Continuous variables are presented as
ean values  SD and categorical variables as frequency (%).
ontinuous variables were compared using independent sam-
le t test. Categorical variables were compared with chi-square
tatistics. Survival free of MACE was estimated using the
aplan-Meier method, and the differences between the two
urvival curves were compared with the log-rank test. The Cox
roportional hazards regression model was used to identify the
ndependent predictors of MACE at six-month follow-up.
he results are presented as hazard ratios (HR) with 95%
onfidence interval (CI). A p value of 0.05 was considered
tatistically significant, and all reported p values are two-sided.
tatistical analysis was performed using SPSS Version 11.5
SPSS Inc., Chicago, Illinois).
ESULTS
aseline clinical characteristics. The baseline clinical char-
cteristics were similar between the two groups, except for a
rend toward a higher incidence of hypercholesterolemia in the
ES group (65.6% vs. 49.4%, p  0.07) (Table 1).
ngiographic and procedural characteristics. Angio-
raphic and procedural characteristics are shown in Table 2.
he percentage of restenotic lesions were significantly
igher in the DES group than in the BMS group (34.8% vs.
.7%, p  0.001). In the DES group, sirolimus-eluting
tents were implanted in 35 patients (57.4%) and paclitaxel-
luting stents in 26 patients (42.6%). Compared to the BMS
roup, the DES group had a smaller mean maximum balloon
iameter (3.35 mm vs. 3.83 mm, p 0.001) and a longer stent
ength per lesion (29.4 mm vs. 20.4 mm, p  0.001).
erial quantitative coronary angiographic analysis. Serial
uantitative coronary angiographic analyses are shown in
able 3. The mean MLD was 1.01 mm for the DES group
nd 1.24 mm for the BMS group (p  0.009). The DES
roup had a trend toward smaller RVD compared to the
MS group (p  0.08). Post-procedure RVD and MLD
ere significantly larger in the BMS group.
Angiographic follow-up was available in 43 patients
71%) (with 50 lesions) in the DES group and 61 patients
69%) (with 86 lesions) in the BMS group. The mean time
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April 5. 2005:989–94 Safety and Efficacy of DES in SVG Lesionso angiographic follow-up was not statistically different
etween the two groups (6.9  3.2 months vs. 6.2  2.1
onths, respectively, p  0.3). Compared to the BMS
roup, late lumen loss was significantly smaller in the DES
roup (0.37  0.97 mm vs. 1.09  1.10 mm, p  0.003).
n-segment restenosis occurred less frequently in the DES
roup (10.0% vs. 26.7%, p  0.03). There was no statistical
ifference regarding the incidence of late occlusion during
ix-month follow-up (6.0% vs. 8.1%, p  0.90).
n-hospital results and clinical follow-up outcomes. In-
ospital results and clinical follow-up outcomes are shown
n Table 4. The incidence of in-hospital MACE was similar
etween the two groups (6.6% vs. 5.6%, p  1.0). Non–Q-
ave MI occurred in four patients (6.6%) of the DES group
nd in five (5.6%) of the BMS group (p  1.0). Among
hose who suffered a non–Q-wave MI in the BMS group,
ne patient (1.1%) died two days after the procedure.
Six-month clinical follow-up was available in all patients.
he cumulative MACE at six months was 11.5% in the
ES group and 28.1% in the BMS group (p 0.02). There
Table 1. Baseline Clinical Characteristics
DES
(n  61
Age, yrs 67
Male, n (%) 51
Family history of CAD, n (%) 23
Hypercholesterolemia, n (%) 40
Hypertension, n (%) 37
Diabetes mellitus, n (%) 12
Prior MI, n (%) 36
Age of SVG, yrs 9.7
Unstable angina, n (%) 18
Multivessel coronary disease, n (%) 59
LVEF, % 50.6
Values are presented as numbers (%) or mean  SD.
BMS  bare-metal stent; CAD  coronary artery disea
fraction; MI  myocardial infarction; SVG  saphenous ve
Table 2. Baseline Lesion and Procedural Char
Lesions characteristics
Location of lesion, n (%)
Ostial
Proximal
Mid
Distal and anastomotic
Restenotic lesions
Total occlusion
Calcium
Thrombus
Procedural characteristics
Number of stents per lesion, n
Mean length of stent per lesion, mm
Maximum balloon diameter, mm
Maximum balloon inflation pressure, atm
No reflow, n (%)
Distal protection devices, n (%)
Glycoprotein IIb/IIIa inhibitors, n (%)Values are presented as numbers (%) or mean  SD.
Abbreviations as in Table 1.ere no statistically significant differences in the cumulative
ncidence of death and MI between the two groups. Com-
ared to the BMS group, the rates of TLR and TVR were
ignificantly lower in the DES group (TLR: 3.3% vs. 19.8%,
 0.003; TVR: 4.9% vs. 23.1%, p  0.003, respectively).
he rate of MACE-free survival was 88.5% in the DES
roup and 71.9% in the BMS group (p  0.03) (Fig. 1).
Cox regression analysis was used to identify independent
redictors of MACE at six months follow-up. Variables
ntered into analysis included: age of patient, age of SVG,
iabetes, hypercholesterolemia, unstable angina, left ven-
ricular ejection fraction, usage of distal protection devices,
dministration of glycoprotein IIb/IIIa inhibitors, duration
f dual antiplatelet therapy, restenotic lesions, occluded
esions, stent type, baseline RVD, lesion length, post-
rocedural MLD, maximal balloon inflation pressure, and
tent length. By Cox regression analysis, diabetes (HR:
.03; 95% CI: 1.33 to 6.90; p 0.008), usage of BMS (HR:
.53; 95% CI: 1.07 to 5.97; p  0.03), and age of SVG
up
ents)
BMS Group
(n  89 Patients) p Value
67  8 0.85
) 79 (88.8) 0.46
) 24 (27.0) 0.21
) 44 (49.4) 0.07
) 48 (53.9) 0.50
) 14 (15.7) 0.66
) 56 (62.9) 0.73
6 9.2  4.8 0.58
) 36 (40.4) 0.23
) 89 (100) 0.32
1 48.7  10.4 0.24
S  drug-eluting stent; LVEF  left ventricular ejection
ft.
stics
S Group BMS Group p Value
 69 n  120
0.46
3 (18.8) 18 (15.0)
2 (31.9) 34 (28.3)
8 (26.1) 27 (22.5)
6 (23.2) 41 (34.2)
4 (34.8) 8 (6.7) 0.001
3 (4.3) 4 (3.3) 0.71
6 (8.7) 6 (5.0) 0.36
9 (13.0) 26 (21.7) 0.18
 61 n  89
0  0.61 1.08  0.30 0.050
4  19.8 20.4  8.8 0.001
5  0.39 3.83  0.58 0.001
7  3.9 15.1  3.5 0.001
0 1 (1.1) 1.0
9 (31.1) 20 (22.5) 0.26
9 (14.8) 19 (21.3) 0.40Gro
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 8
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Safety and Efficacy of DES in SVG Lesions April 5. 2005:989–94HR: 1.10; 95% CI: 1.02 to 1.19; p  0.02) were identified
s predictors of MACE during six-month follow-up.
ISCUSSION
he main findings of this report are that utilization of DES
or treatment of SVG lesions appears safe and feasible and
ES implantation in SVG lesions seems effective in reduc-
ng the incidence of restenosis and improves MACE-free
urvival at six months.
It is estimated that at least 50% of SVG lesions will
evelop stenosis or occlusion within 10 years of implanta-
ion (18). Due to the higher mortality and morbidity
Table 3. Serial Quantitative Coronary Angiogr
DES
Baseline n 
RVD, mm 3.06
MLD, mm 1.01
Diameter stenosis, % 67.6
Mean lesion length, mm 14.8
Post-procedure n 
RVD, mm 3.38
MLD, mm 2.97
Diameter stenosis, % 11.8
Acute gain, mm 1.97
Six-month follow-up, n (%) n 
RVD, mm 3.33
MLD, mm 2.56
Diameter stenosis, % 17.3
Mean lesion length, mm 5.55
Late lumen loss, mm 0.37
In-segment restenosis rate, n (%) 5
Occlusion at follow-up, n (%) 3
Values are presented as numbers (%) or mean  SD.
MLD  minimal lumen diameter; RVD  reference ves
Table 4. In-hospital Results and Clinical Outc
D
(n 
In-hospital
Angiographic success, n (%)
Procedural success, n (%)
In-hospital MACE, n (%)
Cardiac death
Noncardiac death
Q-wave MI
Non–Q-wave MI
TLR
TVR
Stent thrombosis, n (%)
Six-month follow-up
Cumulative six-month MACE, n (%)
Cardiac death
Noncardiac death
Q-wave MI
Non–Q-wave MI
TLR
TVR
Stent thrombosis, n (%)
Values are presented as numbers (%).
MACE  major adverse cardiac events; TLR  target lesion rev
abbreviations as in Table 1.ssociated with repeat bypass surgery, percutaneous revas-
ularization is the preferred approach for treatment of SVG
esions (19). Early results using balloon angioplasty alone to
reat SVG lesions were disappointing (20). Although the
ntroduction of stents achieved more predictable results and
igher success rates, the incidence of restenosis remained
till as high as 37% (3,4).
In comparison with previous studies (3,4), the present
eport enrolled patients with more challenging lesion char-
cteristics, including 18.8% ostial lesions, 4.3% total occlu-
ion, and 34.8% restenotic lesions. These subgroups are
nown to be associated with less favorable outcomes
Analysis
up BMS Group p Value
ions n  120 lesions
65 3.30  0.96 0.08
44 1.24  0.59 0.009
.8 63.9  15.2 0.11
.7 12.8  8.3 0.20
ions n  120 lesions
58 3.67  0.69 0.005
54 3.22  0.73 0.02
5 12.8  9.4 0.45
61 1.97  0.76 0.99
ions n  86 lesions
61 3.32  0.64 1.0
95 2.03  1.05 0.02
.4 33.1  29.7 0.02
41 5.47  3.30 0.73
97 1.09  1.10 0.003
) 23 (26.7) 0.03
7 (8.1) 0.90
meter. Other abbreviations as in Table 1.
at Six-Month Follow-up
roup
atients)
BMS Group
(n  89 Patients) p Value
8.4) 83 (93.3) 0.24
1.8) 80 (89.9) 0.78
.6) 5 (5.6) 1.0
1 (1.1) 1.0
0 —
0 —
.6) 5 (5.6) 1.0
0 —
0 —
0 —
1.5) 25 (28.1) 0.016
2 (2.2) 0.65
.6) 0 0.85
1 (1.1) 0.85
.2) 7 (7.9) 0.82
.3) 18 (19.8) 0.003
.9) 21 (23.1) 0.003
0 —aphy
Gro
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 0.
 0.
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 0.
 0.
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April 5. 2005:989–94 Safety and Efficacy of DES in SVG Lesions1,21,22). However, these lesions treated with DES had a
ignificant improvement in late lumen loss (0.37 0.97 mm
s. 1.09  1.10 mm, p  0.003), resulting in lower
n-segment restenosis rate (10.0% vs. 26.7%, p  0.03).
ompared to the studies using DES implanted in de novo
ative coronary artery lesions, late lumen loss obtained in
he present report appears larger (6,7). It is worth noting
hat three of the five restenotic lesions in the DES group
ere found to be total occlusions, and this fact may have
nfluenced the quantification of the late loss. Late occlusion
s a known problem associated with stenting of SVG lesions.
t is reported that late occlusion occurs in 4% to 7% of the
ases that received BMS (23,24). However, to date, no
ata are available about the rate of late occlusion in SVG
esions after DES implantation. It is also unclear whether
he pattern of restenosis after DES implantation in SVG
esions is different from the one found in native coronary
rteries (25).
Compared to the BMS group, MACE-free survival rates
t six months in the DES group were higher (88.5% vs.
1.9%, p  0.03). By Cox regression analysis, diabetes,
sage of BMS, and age of SVG were identified to be the
redictors of MACE during six-month follow-up. It has
een shown that diabetes is an independent risk factor for
orse clinical and angiographic outcomes in native coronary
rteries and SVG lesions (26–28). Compared to the stent-
ng in SVG lesions of nondiabetic patients, diabetics have
igher TLR and late mortality (27). Marked intimal abnor-
alities and more rapid progression of the atherosclerotic
isease in diabetic subjects may contribute to unfavorable
utcomes (29). Graft age was described as one of the risk
actors for less favorable results in previous studies (30,31).
igure 1. Kaplan-Meier survival curves for freedom from major adverse
ardiac events (MACE) at six-month follow-up. BMS  bare-metal
tents; DES  drug-eluting stents.n the present report, the mean graft age was 9.4 years.Despite the encouraging findings of this report, we
annot ignore that 30% to 50% of late cardiac events (after
ne year) in patients with SVG lesions are due to disease
rogressions at different sites rather than the target one
3,32). This knowledge is important when evaluating the
linical impact of reducing restenosis in SVG lesions after
ES implantation. For these reasons the long-term clinical
enefit of DES in SVG lesions remains to be determined.
djunctive therapies (e.g., treatment of the concomitant
iseases associated with coronary heart disease, extended
ntithrombotic therapy) may be important to impact on late
vents, which may occur independently of restenosis.
tudy limitations. The present report has some limita-
ions: 1) it is a retrospective study; 2) the DES group
ncluded two different types of DES; 3) not all patients
erformed angiographic follow-up; and 4) clinical follow-up
s limited to seven months. Despite these limitations, this
eport represents a large cohort of patients treated on SVG
y DES implantation with complete clinical follow-up.
Some patients with SVG lesions were treated by BMS
etween March 2002 and March 2004. This fact may be
erceived as a selection bias. If anything, these patients had
ery focal lesions or lesions located in large SVGs for which
o appropriately sized DES were available; this group
epresents a lower-risk cohort for TLR. Despite the limi-
ations in this study design, a conclusive randomized trial
omparing DES to BMS appears progressively less feasible
ue to ethical difficulties with treating high-risk cohorts
ith BMS.
onclusions. Percutaneous revascularization in SVG le-
ions with DES appears feasible with a high procedural
uccess rate. Compared to BMS implantation, DES im-
lantation in SVG lesions is associated with a reduction in
he restenosis rate and a beneficial effect on MACE-free
urvival at six-month follow-up.
eprint requests and correspondence: Dr. Antonio Colombo,
MO Centro Cuore Columbus, 48 Via M. Buonarroti, 20145
ilan, Italy. E-mail: info@emocolumbus.it.
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